http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
View Older Stories
-
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
-
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
-
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
-
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
-
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
-
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
-
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
-
Belite Bio to Participate in Three Upcoming Investor Conferences
-
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
-
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
-
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
-
Belite Bio to Present at the JonesHealthcare Seaside Summit
-
Belite Bio to Present at the JonesHealthcare Seaside Summit
-
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
-
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
-
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
-
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
-
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
-
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
-
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
-
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
-
Belite Bio (BLTE) Announces $25 Million Registered Direct Offering
-
Belite Bio Announces $25 Million Registered Direct Offering
-
Belite Bio Announces $25 Million Registered Direct Offering
-
Belite Bio (BLTE) Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
-
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
-
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
-
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
-
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
-
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
-
Belite Bio to Participate in the BTIG Ophthalmology Day
-
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
-
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
-
Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023
-
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
-
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
-
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
-
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
-
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
-
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
-
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
-
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
-
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
-
Belite Bio (BLTE) Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant
-
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
-
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
-
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
